QIAGEN Silicon Valley

Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences

Retrieved on: 
星期四, 二月 22, 2024
Health, Stem Cells, Health Technology, Genetics, Research, Science, Biotechnology, Promega, Sigma-Aldrich, CRISPR, Doctor of Philosophy, Sequence, Marketing, QIAGEN Silicon Valley, QIAGEN, Antibody, Biofuel, Biology, DNA

Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.

Key Points: 
  • Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.
  • Gammack is joining the company as it completes its early access program for complex synthetic genes and gene fragments and prepares for a full commercial service launch.
  • Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.
  • Ansa’s proprietary DNA synthesis platform is based on precise enzymatic reagents that enable ultra-rapid and controlled single-base additions to a DNA molecule.

IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team

Retrieved on: 
星期三, 十一月 15, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Acquisition, Food, Data science, Biology, Takeda, Patient, Immune-mediated inflammatory diseases, Medicine, Informatics, Chief Science Advisor (Canada), Artificial intelligence, Intelligence, Machine learning, Digital, IMID, Biomedical Research, Digital technology, Drug discovery, Digital Insight, QIAGEN Silicon Valley, Knowledge, QIAGEN, Public, Datavant, J&J, Medical device, Immunotherapy

In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.

Key Points: 
  • In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.
  • These additions will play a pivotal role in advancing IMIDomics' mission to accelerate data-driven drug discovery and development aimed at treating IMID patients.
  • Dr. Perakslis brings over two decades of experience in research, digital innovation, data science and technology leadership to IMIDomics.
  • With Eric and Ramon on board, we are confident in our ability to expedite the pace of discovery and innovation at IMIDomics."

Personalis Appoints Christopher Hall as Chief Executive Officer

Retrieved on: 
星期四, 三月 2, 2023
Oncology, Health, Genetics, Health Technology, Pharmaceutical, Biotechnology, Computer science, Systems biology, Harvard Board of Overseers, Cancer, Data science, SVP, Biopsy, Medicine, Chairperson, PSNL, Business administration, CMO, DePauw University, San Jose State University, Informatics, Stanford University, Interim, Genomics, MRD, Executive, Health informatics, Hall, Harvard University, CFO, R, Rich, QIAGEN Silicon Valley, Management, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President.
  • The Board also promoted Aaron Tachibana to the extended leadership position of Chief Operating Officer (COO), effectively immediately, in addition to his role as Chief Financial Officer (CFO).
  • In addition, Dr. Richard Chen has been promoted to the position of Executive Vice President, R&D, effective immediately, in addition to his role as Chief Medical Officer (CMO).
  • Dr. Chen, who joined Personalis in 2011 as Chief Scientific Officer, was previously Senior Vice President, R&D and CMO.

BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis

Retrieved on: 
星期四, 七月 26, 2018
Immunology, Medicine, Biology, Genomics, Health, Omics, Proteomics, Antibody, Immune system, QIAGEN Silicon Valley

The assay brings together high-quality antibodies from the BD Pharmingen portfolio with oligonucleotides, allowing researchers to perform single-cell protein analysis on the BD Rhapsody single-cell analysis system .

Key Points: 
  • The assay brings together high-quality antibodies from the BD Pharmingen portfolio with oligonucleotides, allowing researchers to perform single-cell protein analysis on the BD Rhapsody single-cell analysis system .
  • The product leverages 40 years of BD leadership in immunology research.
  • To advance knowledge of the immune system, BD empowers immunology researchers with a range of tools for multi-omics analysis.
  • "BD is committed to single-cell research and delivering easy-to-use tools with a low barrier to entry," said John Ledek, worldwide president of BD Biosciences.